Subanalysis Results Presented From Real-World CLOUT Registry of Inari Medical’s ClotTriever

January 25, 2021—Inari Medical, Inc. announced interim results of the first 64 chronic deep vein thrombosis (DVT) patients enrolled in CLOUT, the company’s ClotTriever Outcomes Registry. The ClotTriever system has received FDA 510(k) clearance and CE Mark approval for the treatment of DVT.

The subanalysis, which focused on patients with an estimated clot age over 6 weeks, found no serious device-related adverse events were reported across the 14 subanalysis sites. Median blood loss was a modest 50 mL and median thrombectomy procedure time was a short 34 minutes, stated Inari Medical.

The CLOUT registry’s Principal Investigator Steven Abramowitz, MD, presented the findings virtually at LINC 2021, the Leipzig Interventional Course held January 25-29.

“Be it on-going COVID fears, delays in diagnosis, or impediments to referral, many DVT patients have chronic disease by the time they finally meet a DVT interventionist,” commented Dr. Abramowitz in the company’s announcement. “These physicians know that chronic clot is more wall-adherent and collagen-rich, rendering traditional lytic-based tools ineffective. The CLOUT chronic subanalysis has shown us that ClotTriever can offer these chronic DVT patients hope, removing a median 90% of their clot in a single session without the use of thrombolytics.”